This poster presentation, from the 2016 European Society for Medical Oncology (ESMO) Conference in Copenhagen, discusses the results of our Phase 1 clinical trial to study pharmacokinetics and tolerability of PTC596 in humans
ESMO 2016 poster: First-in-human Phase 1 results of PTC596, a novel small molecule that targets cancer stem cells (CSCs) by reducing BMI1 protein levels
GL-CORP-0207 | June 2021
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.